icon
icon
icon
icon
Upgrade
icon

Another piece of good news for the "miracle drug" for weight loss! Lilly's (LLY.US) Trulicity reduced the risk of diabetes in obese people by 94%.

AInvestTuesday, Aug 20, 2024 8:50 am ET
1min read

During a three-year trial, tirzepatide reduced the risk of type 2 diabetes by 94% in adults with prediabetes, obesity or overweight.

Tirzepatide, the active ingredient in Eli Lilly's (LLY.US) diabetes drug Mounjaro and weight-loss drug Zepbound, was found to significantly reduce the risk of type 2 diabetes by 94% in adults with prediabetes, obesity or overweight.

The SURMOUNT-1 study, which assessed tirzepatide in 1,032 adults with prediabetes, obesity or overweight, had a 176-week treatment period, followed by a 17-week post-treatment follow-up (total 193 weeks).

Compared with placebo, weekly injections of tirzepatide (5mg, 10mg, 15mg) significantly reduced the risk of type 2 diabetes by 94% in adults with prediabetes and obesity or overweight.

In addition, tirzepatide maintained weight loss throughout the treatment period. At the end of the treatment period, patients with prediabetes and obesity or overweight taking 15mg had an average weight loss of 22.9%, compared with 2.1% in the placebo group.

During the 17-week post-treatment follow-up, weight began to increase in patients who had stopped taking tirzepatide, and the risk of developing type 2 diabetes increased, but was still 88% lower than placebo.

As of the close, Eli Lilly was up 1.8%, while Novo Nordisk (NVO.US) was down 0.11%.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.